Potential miRNA-based drugs include miR-29b, whose enforced expression in AML cells results in a significant reduction in the expression of DNMT1 and DNMT3A/B at both RNA and protein levels (Yang et al., 2019). Here, DNMT1 is linked to acute myeloid leukemia.